Three years of research and development paid off today when Schwind eye-tech-solutions unveiled the Schwind AMARIS excimer laser to the refractive surgery community. According to CEO Rolf Schwind, it successfully combines all available state-of-the-art technologies in one single system.
It is possible to select aspheric intraocular lenses (IOLs) based on preoperative corneal spherical aberration (SA).
An omni-focal approach, combining an aspheric prebyopic treatment with a hyperopic ablation, looks promising as a method for improving near vision in hyperopes with presbyopia.
Patients should be offered a &34;menu" of options regarding what level of discussion takes place prior to cataract surgery.
Mixing and matching the ReZoom (AMO) and Tecnis (AMO) multifocal intraocular lenses (IOLs) produces enhanced visual outcomes and patient satisfaction.
Dislocation and decentration are, overall, the most common reasons for foldable intraocular lens (IOL) explantation, and the incidence of these complications is rising.
Careful patient selection and precise biometry will all help minimise the risk of later explantation of multifocal IOLs.
Multifocal intraocular lenses (IOLs) are a good choice for the right patient.
Dual optic accommodating IOLs provide a more noticeable positive impact on a patient's quality of life than multifocal IOLs, according to Andrea Galvis and Ivan Ossma of the Instituto para Ninos Ciegos y Sordos, Columbia.
Intracameral mydriatic delivery greatly simplifies cataract surgery.
The psychological outlook of patients has enormous influence on their perception of quality of life after cataract surgery, even if the outcome is poor.
Avastin (bevacizumab) is a useful adjunct for the treatment of neovascular glaucoma, but it is too soon to say if it will have a long-term impact on glaucoma therapy.
The multifocal ReSTOR (Alcon), Tecnis multifocal (AMO) and *Acri.LISA (Acri.Tec) lenses can all provide satisfactory distance and near uncorrected vision.
Patients with Type 2 diabetes undergoing cataract surgery are twice as likely to develop macula oedema than patients without diabetes.
Unlike LASEK, LASIK significantly increases irregular astigmatism in the 3 and 5 mm central zones.
Bausch & Lomb (B&L) today launched its new Stellaris Vision Enhancement system, further demonstrating its dedication to its microincision cataract surgery franchise.
Small incision cataract surgery (SICS) is a highly desirable and effective technique for India and other countries in the eastern hemisphere because it provides a highly effective and economic treatment for the vast cataract population in that part of the world.
Antibiotic-soaked IOLs could present a viable alternative to topical antibiotics for surgeons wanting to provide a sustained release of antibiotic in cataract patients.
At one-year follow-up, the aspheric Akreos Advanced Optics (Adapt AO; Bausch & Lomb) intraocular lens (IOL) achieves better high contrast uncorrected and best corrected visual acuity (UCVA & BCVA) than the conventional spherical Akreos Adapt IOL.
The incidence of spherical aberrations tends to be lower in eyes with aspherical lenses than in eyes with spherical lenses.
When it comes to correcting spherical aberration (SA) of the whole eye, customized IOLs could be a possible approach for the future. However, if high stability of corneal asphericity during cataract surgery is required, it may be necessary to make some improvements to this approach.
Automated lamellar therapeutic keratoplasty (ALTK) and Descemet stripping automated endothelial keratoplasty (DSAEK) are both safe and effective techniques for corneal transplantation.
Wavefront-guided photorefractive keratectomy (PRK) with mitomycin C (MMC) offers very similar results, when correcting compound myopic astigmatism, to wavefront-guided LASIK surgery.
Bausch & Lomb (B&L) has acquired Soothe emolliant eye drops from Alimera Sciences.
Advanced Medical Optics (AMO) has withdrawn its bid to buy Bausch & Lomb (B&L), according to a letter issued to B&L by AMO president, James V. Mazzo. The decision was made after B&L refused to grant more time to AMO to prove that it could gain the support needed from shareholders.
The German Federal Financial Supervisory Authority has approved publication of Alcon's tender offer document for WaveLight AG. This tender offer marks the second step in the completion of Alcon's acquisition of WaveLight.
TareGen has initiated a multicentre Phase II clinical trial for the topically applied TG100801 in patients with age-related macular degeneration (AMD).
Opko Health has initiated the Phase III COBALT (Combining Bevasiranib And Lucentis Therapy) clinical trial of bevasiranib for the treatment of wet age-related macular degeneration (AMD).
Regeneron Pharmaceuticals and Bayer HealthCare have initiated a Phase III study of the VEGF Trap-Eye for the treatment of wet age-related macular degeneration (AMD).
Heidelberg Engineering premiered its new perimeter technology at this year's World Glaucoma Congress in Singapore.